The researchers found that armodafinil did not improve the driving performance of those with OSA after six months of use, the study’s primary outcome, reports Medical Xpress.
Nor did those taking the drug report less daytime sleepiness than those receiving a placebo, as measured by the Epworth Sleepiness Scale and the Functional Outcomes of Sleep Questionnaire.
In the study, 113 participants (ages 18 to 70) were randomly assigned to either receive 150 mg of armodafinil daily or a placebo. Participants had moderate to severe OSA, were moderately obese and did not use continuous positive airway pressure (CPAP) or an oral appliance that advances their lower jaw. Both therapies treat OSA by preventing the pauses in breathing that occur in OSA when the back of the throat collapses.
from Sleep Review http://www.sleepreviewmag.com/2018/05/armodafinil-not-improve-driving-sleep-apnea/